Suven Life Sciences confirms no shares pledged by promoters in FY26

Suven Life Sciences confirmed that shares held by its promoters and promoter group remained unencumbered throughout the financial year ended March 31, 2026. The disclosure ensures that no equity was pledged directly or indirectly by the promoters during FY26, signaling stability in the company's shareholding structure.

The confirmation was submitted to the National Stock Exchange of India Limited and BSE Limited by Venkateswarlu Jasti on behalf of the promoter(s) and promoter group. The filing was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011, which mandates periodic disclosures regarding share encumbrances.

Disclosure Details

The communication explicitly stated that there were no instances of pledging or encumbrance of shares by the promoters during the specified period. This information was provided for the record of the exchanges and the company's Audit Committee.

Entity	Status of Shares	Period
Promoter(s) and Promoter Group	Not encumbered/pledged	FY26

The disclosure was addressed to the Listing Department of the NSE and the Department of Corporate Services of the BSE. A copy of the letter was also forwarded to the Audit Committee of Suven Life Sciences .

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+5.03%	+1.81%	+0.77%	+59.60%	+18.42%	+194.93%

Suven Life Sciences has announced positive topline results from its Phase-2b clinical proof-of-concept trial of Ropanicant for the treatment of Major Depressive Disorder (MDD). The trial demonstrated that twice-daily oral administration of Ropanicant 45 mg resulted in a clinically meaningful improvement in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score at Week 6, the primary endpoint, compared to placebo. The company is now planning a global Phase-3 registrational study for the drug candidate.

Phase-2b Clinical Trial Efficacy

The randomized, double-blind, placebo-controlled trial enrolled 214 patients across 35 sites in the United States for a treatment duration of six weeks. The maximum likelihood (ML) estimated mean difference from baseline versus placebo was -3.572 in the Full Analysis Set (p = 0.038), -3.570 in the modified Full Analysis Set (p = 0.038), and -4.067 in the Per-Protocol Set (p = 0.023). Existing clinical evidence identifies a difference of approximately 2 points in MADRS total score versus placebo as clinically meaningful.

Parameter	Details
Drug Candidate	Ropanicant (SUVN-911)
Trial Phase	Phase-2b
Therapeutic Indication	Major Depressive Disorder (MDD)
Primary Endpoint	MADRS total score change at Week 6
Key Efficacy Result	Mean difference -3.572 (p = 0.038)

Safety and Secondary Endpoints

Ropanicant was generally well tolerated, with the majority of treatment-emergent adverse events reported as mild to moderate. No withdrawal symptoms were observed after discontinuation, and there was no evidence of dissociation. Assessment of clinical laboratory parameters, electrocardiogram (ECG) parameters, and vital signs revealed no clinically meaningful changes. Evidence of treatment benefit was observed across secondary endpoints, including the Clinical Global Impression–Severity of Illness (CGI-S; p = 0.094) and the Sheehan Disability Scale (SDS; p = 0.039).

Strategic Outlook

Suven Life Sciences stated that a priority patent application has already been filed, with an International Application claiming priority to be filed shortly. Mr. Venkat Jasti, Chairman and Managing Director, highlighted the potential of Ropanicant as a differentiated treatment option to meet significant unmet medical needs. Mr. Ramakrishna Nirogi, President and CSO, noted that the company looks forward to engaging with regulatory authorities worldwide to discuss Phase-3 clinical development plans.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE495B01038/55b8bd5d29864b5b.pdf